15003076

Source:http://linkedlifedata.com/resource/pubmed/id/15003076

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0360105, umls-concept:C0380393, umls-concept:C1269683, umls-concept:C1293122
pubmed:issue	2
pubmed:dateCreated	2004-3-8
pubmed:abstractText	Due to their favorable side-effect profile, atypical antipsychotic agents offer important therapeutic advantages in mood disorders. Ziprasidone, an atypical antipsychotic agent with strong 5-HT(1A) agonist activity, may be particularly useful when used in conjunction with standard antidepressants in treatment-resistant depression. The purpose of this study is to test this hypothesis in depressed outpatients who have not experienced significant clinical improvement following an adequate trial of a selective serotonin reuptake inhibitor (SSRI).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7801243
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Piperazines, http://linkedlifedata.com/resource/pubmed/chemical/Serotonin 5-HT1 Receptor Agonists, http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Uptake Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Thiazoles, http://linkedlifedata.com/resource/pubmed/chemical/ziprasidone
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0160-6689
pubmed:author	pubmed-author:AlpertJonathan EJE, pubmed-author:FavaMaurizioM, pubmed-author:MurakamiJessica LJL, pubmed-author:NierenbergAndrew AAA, pubmed-author:PapakostasGeorge IGI, pubmed-author:PetersenTimothy JTJ, pubmed-author:RosenbaumJerrold FJF
pubmed:issnType	Print
pubmed:volume	65
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	217-21
pubmed:dateRevised	2010-11-18
pubmed:meshHeading	pubmed-meshheading:15003076-Adult, pubmed-meshheading:15003076-Antipsychotic Agents, pubmed-meshheading:15003076-Depressive Disorder, Major, pubmed-meshheading:15003076-Dose-Response Relationship, Drug, pubmed-meshheading:15003076-Drug Administration Schedule, pubmed-meshheading:15003076-Drug Resistance, pubmed-meshheading:15003076-Drug Therapy, Combination, pubmed-meshheading:15003076-Female, pubmed-meshheading:15003076-Humans, pubmed-meshheading:15003076-Male, pubmed-meshheading:15003076-Middle Aged, pubmed-meshheading:15003076-Personality Assessment, pubmed-meshheading:15003076-Personality Inventory, pubmed-meshheading:15003076-Piperazines, pubmed-meshheading:15003076-Psychometrics, pubmed-meshheading:15003076-Serotonin 5-HT1 Receptor Agonists, pubmed-meshheading:15003076-Serotonin Uptake Inhibitors, pubmed-meshheading:15003076-Thiazoles, pubmed-meshheading:15003076-Treatment Outcome
pubmed:year	2004
pubmed:articleTitle	Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder.
pubmed:affiliation	Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA. gpapakostas@partners.org
pubmed:publicationType	Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't